Name：WU Shuo

Department：Virology

Tel: (8610) 63165281

Email: wushuo@imb.pumc.edu.cn or wushuoimb@126.com

Education & Research Experience

2019/09 – Now  Associate professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2014/01 – 2019/09 Assistant professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2015/06– 2016/12 Post doctorial fellow, Baruch S. Blumberg institute, Pennsylvania, USA

2011/09 – 2014/07 Ph.D. in Pathogenic biology, Harbin Medical University, Harbin, China

Research Field

Antiviral pharmacology

Research Interests

Dr. Wu has been engaged in the systematic research of antiviral drugs against critical and emerging viruses (mainly focusing on hepatitis B virus and coronavirus), including establishment models in vitro and in vivo, efficacy evaluation, investigation of antiviral molecular targets and mechanism, etc.

As the project leader, Dr. Wu is now responsible for one project supported by the National Natural Science Foundation of China, and has presided over one project of Fundamental Research Funds for the Central Universities as well as its rolling support project. Moreover, as the leader, she has taken charge of one subtask in a sub-project of the Drug Innovation Major Project. As the team backbone, she has participated in several significant projects, including projects of the National Natural Science Foundation of China, the Drug Innovation Major Project, and CAMS Innovation Fund for Medical Sciences, etc.

Selected Publications

In recent 5 years, Dr. Wu has published 9 papers in famous academic journals as the first or corresponding author such as J Virol, Antiviral Res, ACS Med Chem Lett and Int J Antimicrob Agents etc., and published 17 papers as collaborators. The representative papers are shown as follows:

1) Yan H^#, Sun J^#, Wang K^#, Wang H, Wu S, Bao L, He W, Wang D, Zhu A, Zhang T, Gao R, Dong B, Li J, Yang L, Zhong M, Lv Q, Qin F, Zhuang Z, Huang X, Yang X, Li Y*, Che Y*, Jiang J*. Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. Acta Pharm Sin B. 2021. doi: 10.1016/j.apsb.2021.02.024. Epub ahead of print. PMID: 33723501; PMCID: PMC7946546.

2) Cui AL^#, Sun WF^#, Zhong ZJ, Jin J, Xue ST*, Wu S*, Li YH, Li ZR: Synthesis and Bioactivity of N-(4-Chlorophenyl)-4-Methoxy-3-(Methylamino) Benzamide as a Potential Anti-HBV Agent. Drug Des Devel Ther. 2020, 14:3723-3729.

3) Li X^#, Wu S^#, Du Y, Yang L, Li Y*, Hong B*. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents. 2020, 56(1):106000.

4) Luo M, Wu S, Kalkeri R, Ptak RG, Zhou T, Van Mellaert L, Wang C, Dumbre SG, Block T, Groaz E, De Jonghe S, Li Y, Herdewijn P. Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug. J Med Chem. 2020,63 (22), 13851-13860.

5) Lv K^#, Wu S^#, Li W, Geng Y, Wu M, Zhou J, Li Y*, Gao Q, Liu M*. Design, synthesis and anti-HBV activity of NVR3-778 derivatives. Bioorg Chem, 2019, 14:103363.

6) Wang A^#, Wu S^#, Tao Z, Li X, Lv K, Ma C, Li Y*, Li L, Liu M*. Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. ACS Med Chem Lett, 2019, 10(6):991-995.

7) Wu S, Wang HQ, Guo TT, Li YH. Luteolin inhibits CVB3 replication through inhibiting inflammation. J Asian Nat Prod Res, 2019, 19:1-12.

8) Wu S^#, Luo Y^#, Viswanathan U, Kulp J, Cheng J, Hu Z, Xu Q, Zhou Y, Gong GZ, Chang J, Li Y*, Guo JT*. CpAMs induce assembly of HBV capsids with altered electrophoresis mobility: Implications for mechanism of inhibiting pgRNA packaging. Antiviral Res, 2018, 159:1-12.

9) Zhai X^#, Wu S^#, Lin L, Wang T, Zhong X, Chen Y, Xu W, Tong L, Wang Y, Zhao W*, Zhong Z*.  Stress Granule Formation is One of the Early Antiviral Mechanisms for Host Cells Against Coxsackievirus B Infection. Virol Sin., 2018, 33:314-322.

10) Wu S, Zhao Q, Zhang P, Kulp J, Hu L, Hwang N, Zhang J, Block TM, Xu X, Du Y, Chang J, Guo JT. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly. J Virol, 2017, 91(16).

11)Guo F^#, Wu S^#, Julander J, Ma J, Zhang X, Kulp J, Cuconati A, Block TM, Du Y, Guo JT, Chang J*. A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein. J Virol, 2016, 90(23):10774-10788.

Awards and Honors 

2019 Outstanding Communist Party member of Institute of Medicinal Biotechnology, Chinese Academy of Sciences;

2018 “Satoshi ōmura -Zhen Yongsu Youth Science and Technology Award” of Institute of Medicinal Biotechnology, Chinese Academy of Sciences；

2016 “CFF award for women scientists” of the 29^th International Conference on Antiviral Research (ICAR)

Academic Appointments

Dr. Wu is currently the young member of the Anti-infective Pharmacology Committee of Beijing Pharmacological Society.